New patient mobility allows piecemeal capital investments around the EU
This article was originally published in Clinica
Patient mobility comes at a high cost to the smaller countries of the EU, which send their patients to neighbouring countries for treatment due to the lack of availability of services or technology at home. It has the effect of diverting healthcare funds - often to countries with high fees - and this inevitably delays the introduction of new technologies and treatments in the home country.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.